ArticleClinical ophthalmology (Auckland, N.Z.)2026
Optimizing Ocular Surface Disease (OSD) Management in Patients with Glaucoma: Expert Strategies from Asia.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ocular surface disease (OSD) commonly affects glaucoma patients and can occur due to the disease itself and multiple contributing factors, such as the long-term use of preserved topical medications, thereby impacting adherence and treatment outcomes. In Asia, rising glaucoma burden and variability in regional guidelines underscore the need for a practical synthesis of current literature in the region. This review summarizes the OSD treatment landscape in Asia and proposes a pragmatic approach for identifying and managing concomitant OSD in patients with glaucoma. Material and Methods: Eight glaucoma specialists and a cornea expert representing eight Asian countries convened on 8 Results: Regional studies estimate high OSD prevalence among glaucoma patients, with country-level estimates ranging 32.1-99.1% based on symptoms or signs. Risk factors for OSD are similar between Asian and global populations, but Asian ethnicity is a recognized risk factor for dry eye disease. Regional and country-level guidelines for OSD are available but vary in terms of diagnostic criteria, and local awareness of OSD remains lacking. The 3-step approach (Step 1: Assess symptoms and risk factors, Step 2: Slit-lamp examination and staining, Step 3: Tailored management by severity) offers a pragmatic pathway for application in daily clinics. Conclusion: The proposed framework serves as a first step towards harmonizing OSD management in glaucoma patients across Asia, with the potential to enhance the quality of glaucoma care. Further validation of the framework, and increased consensus and awareness may help improve the management of OSD in Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.